I would agree with this quote more then the headline
Maybe, it's fairer to say curing disease can be great for business -- until it's not.
The article underestimates the impact of competition and also would Gilead HCV revenues been so high had they not been "curing" HCV?
But as a GT investor my disagreement is more with the comparison to GT where I believe there are several notable differences some of which include: 1-Its quite unlikely uptake will be as fast with the novelty and "risk" (perceived or actual) of Gene Therapy. 2-A vast majority of GT's being developed are for rare diseases. Most with genetic components this should result in a steady stream of new patients. 3-Gene therapy is still in its infancy. Durability is unknown though many suspect its in the ~10 year range. Also the magnitude of treatment efficacy is far from "cure" (with few possible exceptions).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.